PTC Therapeutics Provides Corporate Update and Reports Third Quarter Financial ResultsPRNewsWire • 10/26/23
PTC Therapeutics Announces Evrysdi® Royalty Agreement with Royalty Pharma for Up To $1.5 BillionPRNewsWire • 10/19/23
PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2023 Financial Results PRNewsWire • 10/16/23
PTC Therapeutics (PTCT) Moves 5.3% Higher: Will This Strength Last?Zacks Investment Research • 10/11/23
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against PTC Therapeutics, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the FirmAccesswire • 10/06/23
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against PTC Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 09/29/23
PTC Announces Further Strategic Prioritization and Associated Reduction in WorkforcePRNewsWire • 09/28/23
PTC Therapeutics (PTCT) Surges 5.8%: Is This an Indication of Further Gains?Zacks Investment Research • 09/20/23
PTC Therapeutics (PTCT) Down on Negative CHMP Opinion for DMD DrugZacks Investment Research • 09/18/23
PTC Therapeutics Crashes 29% After European Regulators Reject Its Muscular Dystrophy DrugInvestors Business Daily • 09/15/23
PTC Therapeutics' 2023 STRIVE Awards Program Funds Initiatives Supporting the Duchenne Patient CommunityPRNewsWire • 09/07/23
PTC Therapeutics to Present Recent Data for Sepiapterin at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual SymposiumPRNewsWire • 08/28/23
PTC Therapeutics (PTCT) Q2 Earnings: How Key Metrics Compare to Wall Street EstimatesZacks Investment Research • 08/04/23
PTC Therapeutics Provides Corporate Update and Reports Second Quarter Financial ResultsPRNewsWire • 08/03/23
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against PTC Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 08/03/23